Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
Loibl, S., Weber, K.E., Timms, K.M., Elkin, E.P., Hahnen, E., Fasching, P.A., Lederer, B., Denkert, C., Schneeweiss, A., Braun, S., Salat, C.T., Rezai, M., Blohmer, J.U., Zahm, D.M., Jackisch, C., Gerber, B., Klare, P., Kümmel, S., Schem, C., Paepke, S., Schmutzler, R., Rhiem, K., Penn, S., Reid, J., Nekljudova, V., Hartman, A.-R., von Minckwitz, G., Untch, M.
Published in Annals of oncology (01.12.2018)
Published in Annals of oncology (01.12.2018)
Get full text
Journal Article
Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)
von Minckwitz, G, Rezai, M, Tesch, H, Huober, J, Gerber, B, Zahm, D.M, Hilfrich, J, Costa, S.D, Dubsky, P, Blohmer, J.U, Denkert, C, Hanusch, C, Jackisch, C, Kümmel, S, Fasching, P.A, Schneeweiss, A, Paepke, S, Untch, M, Burchardi, N, Mehta, K, Loibl, S
Published in European journal of cancer (1990) (01.09.2016)
Published in European journal of cancer (1990) (01.09.2016)
Get full text
Journal Article
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Meyer-Wilmes, P., Huober, J., Untch, M., Blohmer, J.-U., Janni, W., Denkert, C., Klare, P., Link, T., Rhiem, K., Bayer, C., Reinisch, M., Bjelic-Radisic, V., Zahm, D.M., Hanusch, C., Solbach, C., Heinrich, G., Hartkopf, A.D., Schneeweiss, A., Fasching, P., Filmann, N., Nekljudova, V., Holtschmidt, J., Stickeler, E., Loibl, S.
Published in ESMO open (01.05.2024)
Published in ESMO open (01.05.2024)
Get full text
Journal Article